Taxonomy of breast cancer based on normal cell phenotype predicts outcome
View/ Open
Author
Thakkar, Ankita
Ergonul, Ayse
Wang, Bin
Woo, Terri
Harrell, J. Chuck
McNamara, George
Schwede, Matthew
Kindelberger, David
Ince, Tan A.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1172/JCI70941Metadata
Show full item recordCitation
Santagata, Sandro, Ankita Thakkar, Ayse Ergonul, Bin Wang, Terri Woo, Rong Hu, J. Chuck Harrell, et al. 2014. “Taxonomy of Breast Cancer Based on Normal Cell Phenotype Predicts Outcome.” Journal of Clinical Investigation 124 (2) (January 27): 859–870. doi:10.1172/jci70941.Abstract
Accurate classification is essential for understanding the pathophysiology of a disease and can inform therapeutic choices. For hematopoietic malignancies, a classification scheme based on the phenotypic similarity between tumor cells and normal cells has been successfully used to define tumor subtypes; however, use of normal cell types as a reference by which to classify solid tumors has not been widely emulated, in part due to more limited understanding of epithelial cell differentiation compared with hematopoiesis. To provide a better definition of the subtypes of epithelial cells comprising the breast epithelium, we performed a systematic analysis of a large set of breast epithelial markers in more than 15,000 normal breast cells, which identified 11 differentiation states for normal luminal cells. We then applied information from this analysis to classify human breast tumors based on normal cell types into 4 major subtypes, HR0–HR3, which were differentiated by vitamin D, androgen, and estrogen hormone receptor (HR) expression. Examination of 3,157 human breast tumors revealed that these HR subtypes were distinct from the current classification scheme, which is based on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Patient outcomes were best when tumors expressed all 3 hormone receptors (subtype HR3) and worst when they expressed none of the receptors (subtype HR0). Together, these data provide an ontological classification scheme associated with patient survival differences and provides actionable insights for treating breast tumors.Other Sources
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904619/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29004005
Collections
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)